Marijuana and Autism: Exploring Potential Social Benefits & Research

Research on cannabis for autism spectrum disorder (ASD) is limited and inconclusive.

Current Evidence

  • Small open-label studies and surveys report parent-reported improvements in anxiety, agitation, self-injury, sleep, and social communication with CBD-rich or balanced THC:CBD preparations.
  • No large RCTs demonstrate efficacy for core ASD symptoms.
  • Adverse effects: irritability, sedation, cognitive blunting, potential worsening of psychosis risk in vulnerable adolescents.

Major Concerns

  • Developing brain vulnerability (until mid-20s) – cannabis may impair neurodevelopment.
  • Lack of standardized dosing, formulations.
  • Legal/regulatory barriers.
  • No FDA-approved cannabis product for ASD (Epidiolex approved only for Lennox-Gastaut/Dravet seizures).

Clinical Stance

Major academies (AAP, AACAP) do not recommend cannabis for ASD outside clinical trials. Families should discuss with developmental pediatrician, neurologist, or psychiatrist. Behavioral therapies (ABA, CBT), educational supports, and FDA-approved medications (risperidone, aripiprazole for irritability) remain first-line.

Autism - Related Articles